Zobrazeno 1 - 10
of 133
pro vyhledávání: '"J Vandebroek"'
Autor:
F. Verhelst, P. Bertrand, J. Verschuere, S. Marien, L. Roex, Johan Vansteenkiste, A. Verstraete, J. Vandebroek, R. Deman, H. Ulrichts, T. De Beukelaar, Maurits Demedts, J. Bockaert, P. De Muynck, W. Van Kerckhoven
Publikováno v:
Lung Cancer. 13:295-303
The efficacy and toxicity of a regimen adding ifosfamide to the more classical cisplatin-vindesine combination was studied in patients with advanced non-small cell lung cancer. Sixty-four good performance patients with inoperable stage III or stage I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab648bc319740eca999d5c16bb49bd3e
https://doi.org/10.1016/0169-5002(95)00502-1
https://doi.org/10.1016/0169-5002(95)00502-1
Autor:
S. Marien, N L Dams, R C Devogelaere, Yves Humblet, J. Vandebroek, Kristiaan Nackaerts, Y. Valcke, P. Weynants, D A Verresen, Johan Vansteenkiste
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 12(9)
Background: The modest improvement in median survival of advanced non-small-cell lung cancer (NSCLC) by cisplatin-based chemotherapy has led to the current opinion that clinical benefit for the patient is at least as important an end-point as objecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc6d1f6c090cdf20b85b9303e750e592
https://pubmed.ncbi.nlm.nih.gov/11697823
https://pubmed.ncbi.nlm.nih.gov/11697823
Publikováno v:
Palliative medicine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d60c5a485b06670d78be6f7b454b862
https://hdl.handle.net/10067/228570151162165141
https://hdl.handle.net/10067/228570151162165141
Autor:
M, De Brabander, J, Vandebroek, H, Wassenaar, J, De Crée, A, Baisier, B, Demoen, R, De Ridder, E, Jagers, V, Roels, O, Vogels
Publikováno v:
Anticancer research. 15(5B)
Postoperative 5-FU combined with levamisole increases 5 year survival in colon cancer patients (Duke C) by 30% (1). In order to investigate the potential immunological mechanism, we determined lymphocyte subtypes and markers of immune activation in 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::24113146295849e79a60e891a1090e58
https://pubmed.ncbi.nlm.nih.gov/8572636
https://pubmed.ncbi.nlm.nih.gov/8572636
Publikováno v:
Anticancer research. 13(6B)
Erbulozole (R55 104) is a water soluble congener of the microtubule inhibitor tubulozole, which has proven to possess anti-invasive, antitumoral and radiosensitizing capacities. A dose-finding study was performed on respectively 9 patients (every thr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cce51fc0a53c95a2efb172034339f47b
https://pubmed.ncbi.nlm.nih.gov/8135472
https://pubmed.ncbi.nlm.nih.gov/8135472
Autor:
J Vandebroek, R Deridder, G Storme, H Verhaegen, Jagers E, Roels, F Aerts, R Decoster, O Vogels, Baisier A, J Decree, R Doolaege, S Vanbelle, W Distelmans, M Debrabander, M Dewaele, B Demoen
Publikováno v:
International Journal of Oncology.
In search for clues to the potential immunomodulating mechanism of action of levamisole which might be used as monitoring parameters, we have determined a variety of cytokines in the peripheral blood of volunteers and carcinoma patients before and af
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79ce09e8abcf8223f218d267d880dee2
https://doi.org/10.3892/ijo.1.3.337
https://doi.org/10.3892/ijo.1.3.337
Publikováno v:
Anticancer research. 12(1)
Recently, levamisole combined with 5-FU was shown definitively to increase the survival of patients after surgery for colon cancer (9, 10). In the light of these findings the experimental and clinical findings with levamisole in the field of oncology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c7617eac90fdf648f46db74ae206fbef
https://pubmed.ncbi.nlm.nih.gov/1567166
https://pubmed.ncbi.nlm.nih.gov/1567166
Autor:
L.Y. Dirix, W. Wynendaele, Robert Paridaens, Benoit Beuselinck, J Kains, H. Wildiers, Didier Verhoeven, J. Vandebroek
Publikováno v:
Cancer Research. 69:6115
Abstract #6115 Rationale: Taxanes are considered as standard 2nd-line chemotherapy after anthracyclines in metastatic breast carcinoma (MBC). In one large randomized trial, Jones et al. (JCO 2005;23:5542) reported a mean objective remission rate (RR)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53090176eb1ddae2f6cb6020b9500959
https://doi.org/10.1158/0008-5472.sabcs-6115
https://doi.org/10.1158/0008-5472.sabcs-6115
Autor:
Luc Dirix, D. Verhoeven, Robert Paridaens, J. Vandebroek, Jp. Kains, W. Wynendaele, Benoit Beuselinck, H. Wildiers
Publikováno v:
Critical Reviews in Oncology/Hematology. 68:S24
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d1c5798e8ee6837f65a2d869356830d
https://doi.org/10.1016/s1040-8428(08)70046-5
https://doi.org/10.1016/s1040-8428(08)70046-5
Autor:
Kim, Jin Sun1 (AUTHOR) jinsun.kim@tuhs.temple.edu, Gupta, Rohit2 (AUTHOR) rohit.gupta@tuhs.temple.edu
Publikováno v:
Journal of Clinical Medicine. Jan2024, Vol. 13 Issue 1, p241. 16p.